Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT04946734

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine

Effectivity and safety of PFO closure vs medicine in alleviating migraine (SPRING): a multicenter, random, case control study

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Age range

16 year–60 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

Xiamen Cardiovascular Hospital Xiamen University, Xiamen, Fujian, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Presence of PFO with right-to-left shunt, confirmed by Transthoracic.
  • Echocardiography (TTE) or transesophageal echocardiography (TEE) with a bubble study.
  • Bubble study positive confirmed by transcranial doppler.
  • Subject is diagnosed of migraine.
  • Subject signs an informed Consent Form and is willing to participate in follow-up visits

Exclusion criteria

  • Subject is diagnosed of headache with clear etiology.
  • Subject had cerebral hemorrhage, bleeding events in other organs within 3 months or was in high risk of bleeding.
  • Brain CT/MR showed ischemic lesions.
  • Subject is diagnosed of hepatic insufficiency: ALT or AST>3×ULN at the screening visit.
  • Subject is diagnosed of moderate to severe renal insufficiency: eGFR<30ml/min/1.73m2 at the screening visit.
  • Subject has uncontrolled arrhythmia with clinical significance within 90 days.
  • Subject is diagnosed of unstable angina, severe coronary atherosclerosis or myocardial infarction within 90 days.
  • Subject is diagnosed of pulmonary artery embolism, peripheral artery embolism or deep Vein Thrombosis.
  • Subject cannot follow the study procedure due to other acute or chronic diseases.
  • Subject is pregnant or lactating.
  • Subject is under other RCT.
  • Subject has a life expectancy <1 year.
  • Subject cannot follow the study procedure due to other reasons in the opinion of the investigators.

Treatment and study plan

PFO closure device

Device

Device PFO closure.

Aspirin and clopidogrel

Drug

Aspirin 100mg qd for 6 months and clopidogrel 75mg qd administered for 1month after device implanted.

Triptans

Drug

If migraine recurred, Triptans would be administered during the acute phase.

Primary outcomes

  1. Complete cessation of migraine

    Time frame: Month 12

    Primary Efficacy Endpoint

  2. Serious Adverse Event (SAE) related due to device, drug or study procedure

    Time frame: Month 12

    Primary Safety Endpoint

Secondary outcomes

  1. Monthly migraine attacks

    Time frame: Baseline and Month 12

    Mean change of monthly migraine attacks

  2. Monthly migraine days

    Time frame: Baseline and Month 12

    Mean change of monthly migraine days. Monthly migraine days = migraine attacks in one month × average time period per attacks (hours) /24 hours

  3. Responder rate

    Time frame: Baseline and Month 12

    Percentage of subject with at least 50% reduction in monthly migraine attacks from baseline

Sponsors and collaborators

Lead sponsor

Guangdong Provincial People's Hospital

Other

Registry information

Official study title

Effectivity and Safety of PFO Closure vs Medicine in Alleviating Migraine (SPRING): a Multicenter, Random, Case Control Study

Acronym: SPRING

Important dates

Study start
2021
Primary completion
2025
Study completion
2025
First posted
Jul 1, 2021
Registry last updated
Mar 12, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.